乳腺癌
细胞毒性T细胞
外周血单个核细胞
免疫系统
癌症
CD8型
转移
癌细胞
T细胞
病理
医学
淋巴结
原发性肿瘤
抗原
获得性免疫系统
免疫学
癌症研究
生物
内科学
体外
生物化学
作者
Xuelian Song,Changran Wei,Xiangqi Li
标识
DOI:10.1016/j.intimp.2021.108457
摘要
The roles of γδ T cells in patients with breast cancer (BC) have not been fully clarified, although the efficacy of gamma delta (γδ) T cells, which combine both innate and adaptive potential have extraordinary properties, such as recognizing tumor cells without the need for major histocompatibility complex (MHC) antigen presentation, as well as killing a broad range of tumor cells through their strong cytotoxic and pro-inflammatory activity, has been suggested in the majority of patients with some certain cancers.To understand and dissect the association between γδ T cells and the clinical pathology of BC by measuring and analyzing the γδ T cell populations in the patients with BC.On the one hand, γδ T cells were measured and analyzed by extracting from peripheral blood mononuclear cells (PBMC) of patients with BC. On the other hand, γδ T cells were measured and analyzed by performing enzymatic digestion in primary BC tissues, cancer adjacent tissues, and distant normal breast tissues from patients with different stages of cancer progression. In addition, patients with breast benign tumors and healthy volunteers were also collected as controls for this study.The proportion of γδ T cells in PBMC was significantly correlated with tumor histological grade, ER status, the proportional value of Ki-67, and lymph node (LN) metastasis. The decrease and exhaustion of γδ T cells were a general feature in the PBMC of BC patients. In addition, the primary BC tissue infiltration of γδ T cells was significantly associated with tumor histological grade, ER status, the proportional value of Ki-67, and LN metastasis.These findings suggest that γδ T cell populations are crucial for understanding the clinicopathological features of patients with BC, and may serve as a valuable and independent biomarker, as well as a potential therapeutic target for human BC.
科研通智能强力驱动
Strongly Powered by AbleSci AI